IMNN
Price
$5.41
Change
-$0.17 (-3.05%)
Updated
Sep 16, 04:53 PM (EDT)
Capitalization
14.07M
62 days until earnings call
STOK
Price
$23.14
Change
-$0.26 (-1.11%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
1.28B
56 days until earnings call
Interact to see
Advertisement

IMNN vs STOK

Header iconIMNN vs STOK Comparison
Open Charts IMNN vs STOKBanner chart's image
Imunon
Price$5.41
Change-$0.17 (-3.05%)
Volume$4.51K
Capitalization14.07M
Stoke Therapeutics
Price$23.14
Change-$0.26 (-1.11%)
Volume$12.29K
Capitalization1.28B
IMNN vs STOK Comparison Chart in %
Loading...
IMNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMNN vs. STOK commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNN is a Hold and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (IMNN: $5.58 vs. STOK: $23.40)
Brand notoriety: IMNN and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNN: 16% vs. STOK: 93%
Market capitalization -- IMNN: $14.07M vs. STOK: $1.28B
IMNN [@Biotechnology] is valued at $14.07M. STOK’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNN’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • IMNN’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than IMNN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNN’s TA Score shows that 3 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • IMNN’s TA Score: 3 bullish, 4 bearish.
  • STOK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, STOK is a better buy in the short-term than IMNN.

Price Growth

IMNN (@Biotechnology) experienced а -4.12% price change this week, while STOK (@Biotechnology) price change was +6.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.28%. For the same industry, the average monthly price growth was +6.89%, and the average quarterly price growth was +33.83%.

Reported Earning Dates

IMNN is expected to report earnings on Nov 17, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+3.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.28B) has a higher market cap than IMNN($14.1M). STOK YTD gains are higher at: 112.149 vs. IMNN (-54.968). STOK has higher annual earnings (EBITDA): 42.3M vs. IMNN (-14.79M). STOK has more cash in the bank: 248M vs. IMNN (4.73M). IMNN has less debt than STOK: IMNN (1.19M) vs STOK (2.3M). STOK has higher revenues than IMNN: STOK (200M) vs IMNN (0).
IMNNSTOKIMNN / STOK
Capitalization14.1M1.28B1%
EBITDA-14.79M42.3M-35%
Gain YTD-54.968112.149-49%
P/E RatioN/A26.97-
Revenue0200M-
Total Cash4.73M248M2%
Total Debt1.19M2.3M52%
FUNDAMENTALS RATINGS
IMNN vs STOK: Fundamental Ratings
IMNN
STOK
OUTLOOK RATING
1..100
220
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10046
PRICE GROWTH RATING
1..100
9535
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMNN's Valuation (57) in the Medical Specialties industry is in the same range as STOK (62) in the null industry. This means that IMNN’s stock grew similarly to STOK’s over the last 12 months.

IMNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STOK (100) in the null industry. This means that IMNN’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for IMNN (100) in the Medical Specialties industry. This means that STOK’s stock grew somewhat faster than IMNN’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is somewhat better than the same rating for IMNN (95) in the Medical Specialties industry. This means that STOK’s stock grew somewhat faster than IMNN’s over the last 12 months.

STOK's P/E Growth Rating (8) in the null industry is significantly better than the same rating for IMNN (100) in the Medical Specialties industry. This means that STOK’s stock grew significantly faster than IMNN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNNSTOK
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 7 days ago
89%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 6 days ago
86%
Declines
ODDS (%)
Bearish Trend 13 days ago
89%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IMNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ITRN36.191.22
+3.47%
Ituran Location and Control Ltd
RYDE0.400.01
+2.24%
Ryde Group Ltd
FIG54.121.05
+1.98%
Figma Inc
VC123.93-0.66
-0.53%
Visteon Corp
BFIN12.11-0.15
-1.26%
BankFinancial Corp

IMNN and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNN has been loosely correlated with ABVX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNN jumps, then ABVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNN
1D Price
Change %
IMNN100%
-2.96%
ABVX - IMNN
58%
Loosely correlated
+2.21%
REPL - IMNN
57%
Loosely correlated
-1.05%
MRUS - IMNN
35%
Loosely correlated
-2.14%
CLSD - IMNN
30%
Poorly correlated
-17.58%
STOK - IMNN
30%
Poorly correlated
-0.26%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-0.26%
QTTB - STOK
49%
Loosely correlated
-6.22%
IMNM - STOK
47%
Loosely correlated
+2.93%
SYRE - STOK
47%
Loosely correlated
-5.18%
DNLI - STOK
46%
Loosely correlated
-7.26%
IDYA - STOK
46%
Loosely correlated
-0.33%
More